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Abstract
Background: Due to their “natural immune privilege” and immunoregulatory properties human fibroblast-like
limbal stem cells (f-LSCs) have acquired great interest as a potential tool for achieving immunotolerance. Hashimoto’s
thyroiditis (HT) is the most common thyroid autoimmune disease and cause of hypothyroidism. To date, conventional
hormone replacement therapy and unspecific immunosuppressive regimens cannot provide a definitive cure for HT
subjects. We explored the immunosuppressant potential of human f-LSCs on circulating lymphomonocytes (PBMCs)
collected from healthy donors and female HT patients.
Methods: We assessed the immunophenotyping of f-LSCs, both untreated and after 48 h of proinflammatory cytokine
exposure, by means of quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and flow cytometry. The
immunosuppressant effects of f-LSCs on healthy activated PBMCs were investigated in cell-cell contact and transwell
settings through cell cycle assay, acridine orange staining, and caspase-3 detection. We also studied T-cell responses and
possible Treg conversion by means of flow cytometry. Functional assays were conducted in activated HT lymphocytes
cocultured with f-LSCs after carboxyfluorescein succinimidyl ester labeling and intracellular detection of pro- and anti-
inflammatory cytokines.
Results: The hypo-immunogenicity of the f-LSC population depended on both cell contact and soluble factors
produced, as well as the undetectable expression of all those molecules required to fully activate T lymphocytes.
Following exposure to Th1 cytokines, f-LSCs augmented expression of programmed death-ligand 1 and 2 (PDL-1 and
-2), indoleamine-pyrrole-2,3-dioxygenase (IDO), interleukin (IL)-6, and monocyte chemotactic protein 1 (MCP-1) while
maintaining their negative phenotype for major histocompatibility (MHC) class II and costimulatory molecules. During
coculture, f-LSCs suppressed up to 40% of proliferation in healthy activated PBMCs, arrested them in the G0/G1 cell
cycle phase without inducing apoptosis cascade, inverted the CD4/CD8 ratio, and promoted sustained expression of
the immunomodulator marker CD69. Under coculture conditions the Th imbalance of autoreactive T cells from female
HT patients was fully restored.
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Conclusions: Our study describes an in vitro coculture system able to prevent inappropriate activation of autoreactive
T lymphocytes of female HT patients and to generate a tolerogenic environment even in an inflammatory background.
Further investigations are necessary to establish whether this stem cell-based therapy approach in HT could avoid
lifetime hormone replacement therapy by inducing T-cell education.
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Inflammatory diseases
Background
It has been proposed that mesenchymal stem cells
(MSCs) can contribute to the control of inflammatory
diseases, as has been demonstrated by the MSC-
mediated attenuation of inflammation in myocarditis [1],
rheumatoid arthritis [2], and experimental autoimmune
diseases [3, 4]. Due to their regenerative and immuno-
suppressive properties, MSCs derived from different
adult tissue have become a preferred cell type in the field
of regenerative medicine and immunotherapy. Although
bone marrow is considered a universal source of multi-
potent MSCs (BM-MSCs), displaying the greatest sup-
pressive effects on T-cell proliferation, the invasive
procedure necessary to harvest these cells, the risks of
complications, and the age-dependent decline of their
self-renewal capacity have led to a search for alternate
sources of MSCs. Cord blood-derived MSCs (CB-MSCs),
placenta-derived MSCs (P-MSCs), and adipose-derived
MSCs (A-MSCs) have been suggested as alternative
sources of MSCs for experimental and clinical purposes
since they are free from ethical concerns, easy to pro-
cure, and available in large quantities. Despite this, only
BM- and A-MSCs have the trilineage differentiation po-
tential satisfying the minimal criteria for an MSC as de-
fined by the International Society for Cellular Therapy
[5]. Furthermore BM-, CB-, and A-MSCs exhibited repli-
cative senescence when they reached passage 10 on aver-
age, whereas P-MSCs expanded until passage 15 [6]. An
attempt at a stem cell educator therapy induced by CB-
MSCs has already been described [7–9], but only in type
1/2 diabetes and alopecia areata. Limitations for the use
of CB-MSCs include insufficient quantity and quality of
MSCs obtainable from a single unit of CB, the potential
for transfer of genetically abnormal or premalignant cells
in patients, and the lack of a National Cord Blood Policy
able to manage daily operations of cord blood banking
and allocation nationwide.
Nowadays, increasing attention is focusing on applica-
tion of limbus-derived cells in regenerative medicine.
This area of the eye is placed in the junction of the cor-
nea and conjunctiva. It is extensively used for ocular sur-
face resurfacing in patients with limbal stem cell
deficiency (LSCD). The cornea is devoid of blood vessels
and is assumed to give protection against immune
rejection of transplanted grafts, a condition termed “cor-
neal immune privilege” [10]. Its avascularity implies a
lack of angiogenic factors or the possibility that it may
secrete antiangiogenic factors. In addition, the absence
of corneal lymphatic vessels prevents channeling of
antigen-presenting cells to the regional lymph nodes.
Moreover, immune tolerance in the anterior chamber is
responsible for the success rate of corneal transplant-
ation [11]. In this connection, the limbus is a highly spe-
cialized region of the eye hosting a well-recognized
population of limbal epithelial stem cells (LESCs), which
continuously renew the corneal surface [12]. There is
more recent evidence that the limbal niche also hosts
stromal fibroblast-like stem cells (f-LSCs) with multiline-
age transdifferentiation potential [13]. We recently
demonstrated that f-LSCs represent a robust source
of adult stem cells with differentiation potential to-
wards the pancreatic endocrine cell fate, good prolif-
erative capability, and long-term maintenance of stem
cell properties independently of donor age and long-
term culture conditions [14, 15].
Autoimmune thyroid disease (AITD) is the most com-
mon thyroid disease. These organ-specific autoimmune
disorders include intrathyroidal lymphocyte infiltration,
presence of circulating thyroid autoantibodies, immuno-
logical overlap with other autoimmune diseases, and a
history of familial occurrence, mainly in females. It oc-
curs due to loss of tolerance to thyroid autoantigens
such as thyroperoxidase (TPO), thyroglobulin (Tg), and
thyroid stimulating hormone receptor (TSH-R) leading
to T- and B-cell infiltration into the gland [16]. The de-
struction of thyroid parenchyma in Hasimoto’s thyroid-
itis (HT) is mostly due to gland infiltration by cytotoxic
T cells, production of autoantibodies, and cytokine-
mediated induction of Fas on thyrocytes, which constitu-
tively express FasL [17]. Various cytokines are found in
thyroid follicular cells which enhance inflammatory re-
sponse with nitric oxide (NO) and prostaglandins [18]. In
particular, interferon (IFN)-γ is a proinflammatory cytokine
that induces expression of human leukocyte antigen class
II (HLA-DR) molecules in many cell types including BM-
MSCs. We showed that f-LSCs, unlike other kinds of
MSCs, do not modify their immuno-privileged condition,
even if an inflammatory background exists, acting as
Coppola et al. Stem Cell Research & Therapy  (2017) 8:154 Page 2 of 14
“smart immunomodulators”. Ultimately their in vitro im-
munosuppressant capability offers a novel concept of stem
cell-based therapy for the treatment of a complex disease
such as HT with unknown pathogenesis and currently
monitored through a symptomatic therapy merely based
on administration of synthetic thyroid hormone. Our aim
was to evaluate the ability of f-LSCs to exert immunomo-
dulation on peripheral blood mononuclear cells (PBMCs)
from female HT patients studying different mechanisms.
Methods
Isolation of limbal stem cells
Human corneo-scleral rings from donors were processed
as previously described [14]. The study was approved by
the Ethical Committee of the AOUP, University of Pa-
lermo (No. 09/2009).
Briefly, samples underwent fine dissection with a ster-
ile blade and were subsequently incubated with collage-
nase I (5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA)
overnight at 37 °C in a shaking bath and the day after
placed in p60 culture dishes (Corning, New York, USA)
with the fibroblast maintenance medium (Dulbecco’s
modified Eagle’s medium (DMEM)/F12 supplemented
with 10% embryonic stem cell-tested fetal bovine serum
(EC-FBS; PAA Laboratories Gmbh, Austria), 1× 5 μg/ml
insulin, 5 μg/ml transferrin, and 5 μg/ml selenium (ITS;
PAA Laboratories), and 20 ng/ml basic fibroblast growth
factor (b-FGF; Preprotech, London, UK) until cells
reached confluence. The f-LSC subcultures were kept in
the expansion medium (DMEM/F12 supplemented with
5% EC-FBS (PAA Laboratories), 1× ITS (PAA Laborator-
ies), and 4 ng/ml b-FGF (Preprotech)) up to passage 20.
Patient selection
Thirty-one female patients aged between 28 and 66 years
with autoimmune thyroiditis and elevated plasma TPO
antibodies (TPOAb) and/or Tg antibodies (TgAb) were
selected at the Outpatient Clinic of the Section of Endo-
crinology, Policlinico P. Giaccone, University of Palermo,
and asked for their informed consent to participate in
the study. Diagnoses had been made using elevated
TPOAb/TgAb. All patients were receiving L-T4 replace-
ment therapy in a dosage to maintain basal TSH within
the normal range. Patients with a history of allergies,
other chronic diseases (e.g., diabetes, hypertension, cor-
onary heart, viral hepatitis), or receiving corticoids or
other anti-inflammatory therapies were excluded from
the study. The healthy control group comprised 18 sub-
jects: 12 males and 6 females aged 24–34 years. Fifteen
milliliters of heparin anticoagulated blood was drawn
from each donor/patient in the morning after a 12-h
fasting period. The blood was diluted 1:1 with
phosphate-buffered aline (PBS) solution, and PBMCs
were separated by gradient centrifugation over Ficoll
(Lympholyte-Human Cell Separation Media, Cedarlane,
Burlington, Canada) according to the manufacturer’s
instructions.
Isolation of T cells
For some experiments untouched T cells were purified
using the Human Pan T Cell Isolation Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). The purity of isolated cells
was >95% as assessed by flow-cytometric analysis. Viability
(>95%) was determined by Trypan blue exclusion.
Cocultivation experiments
PBMCs obtained by Ficoll-Paque density gradient or puri-
fied T cells were cultured in complete RPMI-1640 (PAA
Laboratories) supplemented with penicillin-streptomycin
solution (SigmAldrich, Milan, Italy) and 10% heat-
inactivated fetal bovine serum (bovine serum albumin
(BSA); PAA Laboratories). In coculture experiments the
PBMCs were activated for 72 h with 5 μg/ml of mAb anti-
human CD3 (OKT-3 Clone, SigmAldrich). The T cell puri-
fied culture was supplied with the OKT-3 Clone mAbs
along with 1 μg/ml of anti-human CD28 mAbs (SigmAl-
drich) for the same time period. f-LSCs were seeded at
2000 cells/cm2 and allowed to adhere in 24-well or 6-well
plates (Corning Co., Corning, NY) overnight. After 24 h
they were cocultured with total PBMCs or purified T cells
at a 1:50 or 1:100 ratio, respectively. Preliminary experi-
ments were performed to establish the optimal cell ratio by
varying the f-LSCs concentration. The low f-LSC/PBMC
ratio in the flasks prevented f-LSC detachment while the
PBMCs or T cells were gently recovered as supernatant for
FACS and quantitative reverse transcription polymerase
chain reaction (qRT-PCR) analyses. For some experiments
the stimulated PBMCs were directly plated in 0.4-μm
Transwell inserts (Corning Co.) and put in a 24 well-plate
in which f-LSCs were precultured for 72 h. PBMCs/T cells
without TCR stimulation were used as negative controls.
Cytokine prelicensing of f-LSCs was performed by adding
500 U/ml of recombinant human IFN-γ, interleukin (IL)-
1β, and IL-6 (all by Peprotech, Rocky Hill, NJ, USA) for
48 h. In all coculture experiments BM-MSCs were used as
internal positive controls of stemness. The best PBMC/
BM-MSC ratio used was 1:10, as reported in many previ-
ous in vitro studies [19, 20].
Isolation of total RNA and qRT-PCR
Total RNA was extracted and purified from PBMCs or
f-LSCs using the RNeasy Mini Kit (Qiagen, Milan, Italy),
including a digestion step with DNase I step according
to the manufacturer’s protocol. RNA quantity and qual-
ity were assessed by means of UV spectrophotometry;
1 μg total RNA were reverse transcribed in a volume of
20 ml with Oligo dT primers (Applied Biosystems,
Darmstad, Germany) and Stratascript RT (Stratagene,
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Amsterdam, Netherland), according to the manufac-
turer’s protocol. The primer pair sequences are listed in
Table 1. The primer sets for HLA-G were selected to
amplify all alternative forms of HLA-G transcripts. PCR
primers for IL-6, FAS, IDO, MCP1, CCND1, and p27
were purchased from Qiagen (QuantiTect Primer As-
says, Qiagen, Milan, Italy). All reactions were performed
with Quantitect Sybr Green PCR Kit (Qiagen) using the
Rotor-Gene Q instrument (Qiagen). The specificity of
the amplified products was determined by means of
melting peak analysis. Relative gene expression analysis
for each gene was performed with Rotor-Gene Q soft-
ware using the Delta Delta Ct method validated accord-
ing to the guidelines of Livak and Schmittgen [21]. All
reactions were performed at least in triplicate.
Cell cycle assays
Cell cycles were performed according to the protocol of
Nicoletti et al. [22] and analyzed by flow cytometry
(FACSCalibur, Becton Dickinson). Briefly, cell suspen-
sions were fixed in 70% ethanol and stained with propi-
dium iodide (PI) overnight before FACS analysis.
Acridine orange/ethidium bromide staining
PBMC suspensions (106) after 72 h of coculture were in-
cubated with 1 μl acridine orange/ethidium bromide
(AO/EB) solution (5 mg/ml and 3 mg/ml, respectively,
in PBS) and mixed gently. Then 10 μl of each stained
sample was placed onto a microscopic slide cover with a
glass coverslip and immediately evaluated under a fluor-
escence microscope using a fluorescein filter in a 40×
objective. Jurkat cells treated for 4 or 24 h with human
activating anti-Fas antibody (CH11 clone) were used as
apoptotic positive controls.
AO/EB staining was also performed in f-LSCs. They
were cultured in chamber slides (BD Biosciences) for
48 h with or without Th1 cytokines (IL-1β, IL-6, IFN-γ)
and afterwards stained as described above.
Flow cytometry
The cells were treated with FcR blocking reagent (Miltenyi
Biotec, Bergisch Gladbach, Germany) and incubated with
each fluorochrome-conjugated antibody or appropriate
isotype control at 4 °C for 30 min in the dark. Cells were
then fixed for 15 min at 4 °C with 2% paraformaldehyde
(PFA) and washed with staining buffer (PBS, calcium and
magnesium free, supplemented with 1% BSA (Sigma-Al-
drich)). The T-cell phenotype was determined using CD25
PerCP-Cy™5.5, FoxP3 (Scurfin, IPEX, JM2) PE, CD4 FITC,
CD69 PE, CD8 FITC/PE, CD3 FITC, CD152 (CTLA-4)
PE, CD28 (TLR2) PE, IFN-γ PE, IL-4 PE, IL-17 PE, RORγt
PE, and IL-10 PE (all purchased from BD Biosciences,
Milan, Italy). Intracellular staining was performed using
BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit
(with BD GolgiStop™ protein transport inhibitor) (BD Bio-
sciences, Milan, Italy) according to the manufacturer’s in-
structions. For cytokine detection, BD GolgiStop protein
transport inhibitor containing monensin was added to the
culture for 5 h before cell harvesting.
The f-LSC immunophenotype was determined using the
following monoclonal antibodies: HLA-DR FITC, CD80
(B7-1) PE, CD86 (B70/B7-2) PE, PD-1 (CD279) PE, CD34
FITC, CD45 FITC, CD274 (B7-H1, PD-L1) PE, CD273
(B7-DC, PD-L2) PE, and B7-H4 PE (BD Biosciences).
Freshly isolated PBMCs and primary CD34+ BM-MSCs
(Lonza, Basel, Switzerland; catalogue number 2 M-101C)
were used as positive controls for hematopoietic and stem
cell/immunosuppressive markers, respectively. For apop-
tosis detection, active caspase-3 antibody, reported to spe-
cifically recognize the active form of caspase-3 in humans,
was used (BD Biosciences). All data were acquired on a
FACSCalibur and analyzed using CELLQuest Pro software
(BD Pharmingen, San Jose, CA, USA).
MTT assay
Cell proliferation was assessed by colorimetric assay
using 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazo-
lium bromide (MTT) according to Mosmann’s protocol
[23]. f-LSCs with or without cytokines were plated in a
96-well plate with 100 mL medium/well and cultured
for up to 72 h. The proliferation rate was evaluated by
UV absorption spectrum at 550 nm, after MTT incuba-
tion for 4 h at 37 °C.
Proliferation assay
PBMCs from healthy donors or female HT patients were
labeled with CellTrace carboxyfluorescein succinimidyl
ester (CFSE) using the Cell Proliferation Kit (Molecular
Table 1 Primer sequences used for RT-PCR analysis
Gene Primer sequence
PDL1 (CD274) Forward primer 5′ TTGCTGAACGCCCCATACAA 3′
Reverse primer 5′ GGAATTGGTGGTGGTGGTCT 3′
TGF β1 Forward primer 5′ GTGGACATCAACGGGTTCACT 3′
Reverse primer 5′ ATGAGAAGCAGGAAAGGCCG 3′
FasL Forward primer 5′ GCAGCCCTTCAATTACCCAT 3′,
Reverse primer 5′ CAGAGGTTGGACAGGGAAGAA 3′
AIRE Forward primer 5′ CGGGGGTATAACAGCGGC 3′
Reverse primer 5′ CCTCAGAAGCCGGCGTAG 3′
HLA-G Forward primer 5′CTGGTTGTCCTTGCAGCTGTAG 3′
Reverse primer 5′ CCTTTTCAATCTGAGCTCTTCTTTCT 3′
COX2 Forward primer 5′ ATCATTCACCAGGCAAATTGC 3′,
Reverse primer 5′ GGCTTCAGCATAAAGCGTTTG 3′
HGF Forward primer 5′ CTC ACA CCC GCT GGG AGT AC 3′
Reverse primer 5′ TCC TTG ACC TTG GAT GCA TTC 3′
AIRE autoimmune regulator, COX2 cyclooxygenase-2, HGF hepatocyte growth
factor, HLA-G human leukocyte antigen G, PDL1 programmed death-ligand 1,
RT-PCR reverse-transcription polymerase chain reaction, TGF transforming
growth factor
Coppola et al. Stem Cell Research & Therapy  (2017) 8:154 Page 4 of 14
Probes Invitrogen, Milan, Italy), according to the manu-
facturer’s instructions. Labeled PBMCs were resus-
pended in RPMI 1640 medium with 10% FBS, activated
with 5 μg/mL of anti-CD3 mAbs and cocultured with 1-
day plated f-LSCs. After 7 days of coculture PBMCs
were gently harvested from the supernatant and CFSE
fluorescence detected by flow cytometry. Samples were
analyzed by Modfit LT Version 3.2 software (Verity Soft-
ware House) and the proliferation index calculated as
the sum of cells in all generations divided by the number
of original parent cells.
Statistical analysis
All assays were performed in triplicate. The data are re-
ported as means ± SD and compared using the appropri-
ate version of the Student’s unpaired t test. Test results
were reported as two-tailed p values, where p < 0.05 was
considered statistically significant.
Results
Immunophenotype of f-LSCs
f-LSCs at a relatively early passage (passage 1–10) exhib-
ited the expected fibroblast-like morphology and
expressed the phenotypic markers shown in Fig. 1a (left
panel) and 1b (upper graph). qRT-PCR and flow cytome-
try analysis were performed to determine the presence
of key factors involved in immunoregulation. Up to pas-
sage 20 over 95% of growing cells were negative for the
costimulatory molecules CD80 (B7-1), CD86 (B70/B7-2),
HLA-DR, the immune T-activator molecule pro-
grammed death-1 (PD-1, CD279), the hematopoietic
markers CD34 and CD45, and the epithelial marker
Δp63. By contrast, the majority of them expressed the
stemness markers SSEA4, SOX2, CD105, OCT4,
NANOG, and CD90 and were able to differentiate into
adipocytes, chondrocytes, osteocytes and insulin-
producing cells as previously published [13, 14]. It was
found that f-LSCs constitutively expressed, and at the
same levels as BM-MSCs, transcripts required to modu-
late an immune response such as transforming growth
factor (TGF)-β, programmed death-ligand 1 (PDL-1),
the autoimmune regulator (AIRE), and FAS (CD95). The
weak expression for CD95 and the total absence of ex-
pression for CD95 ligand (CD95L) in f-LSCs did not
suggest a Fas-FasL mediated immunoregulation. In con-
trast, constitutive HLA-G, indoleamine-pyrrole 2,3-diox-
ygenase (IDO), and IL-6 expression were approximately
four- to fivefold lower compared to the positive controls.
The primer set used in this study detected both the
HLA-G membrane bound (HLA-G1, G2, G3, and G4)
and soluble isoforms (HLA-G5, G6, and G7) [24]. Inter-
estingly, expression of hepatocyte growth factor (HGF),
cyclooxygenase-2 (COX-2), and monocyte chemotactic
protein-1 (MCP-1 or CCL2) was found to be 10-, 50-,
and 90-fold higher, respectively, in f-LSCs compared to
BM-MSCs. In addition, f-LSCs showed an appreciably
constitutive expression for CD274 (PDL-1) and CD273
(PDL-2) (39.0 ± 5.1%; 66.0 ± 3.4%) and the absence of the
negative regulator of T cell response B7-H4 (2.1 ± 0.5%)
at the protein level. Taken together, these findings sug-
gested that the f-LSCs exhibited the machinery required
to induce immunomodulation and immunosuppression.
Proinflammatory ‘licensing’ of f-LSCs
In contrast to therapies that cause global immune sup-
pression, some MSCs have been dubbed as “smart im-
mune modulators” since their suppressive effects require
a previous licensing step that occurs in the presence of
an inflammatory milieu and is mediated by the secretion
of specific cytokines [25]. To explore this phenomenon
in f-LSCs we cultured them with several Th1-related cy-
tokines (IL-1β, IL-6, and IFN-γ at 500 U/ml) for 48 h
miming in vitro the inflammatory environment provided
from lymphocytes in HT. Next we assessed their immu-
nophenotyping by qRT-PCR and flow cytometry. FACS
analysis showed an increase in PDL-1 and PDL-2 protein
expression (40.5 ± 2.3% vs. 91.0 ± 3.5% and 66.8 ± 4.2%
vs. 86.5 ± 2.5%, respectively; p < 0.02) and no significant
changes for CD80, CD86, B7H4, PD-1, and HLA-DR
(Fig. 1a, right panel). Our results also showed mainten-
ance at baseline of mRNA for HLA-G, TGF-β, and
AIRE. Expression of COX-2 and HGF was preserved at
sustained levels without significant variations. The apop-
totic marker CD95 halved in expression while CD95L
was still totally absent. Notably, mRNA for IDO and
PDL-1 was found to be upregulated twofold compared
to untreated controls while the mRNA for IL-6 and
MCP-1 increased 25- and 60-fold, respectively (Fig. 1b,
lower graph). During stimulation f-LSCs appeared to
show regular morphology when compared to the un-
treated negative controls (Fig. 1c) and to grow moder-
ately faster, as shown by the MTT assay (Fig. 1d). Taken
together, these data confirmed the capability of f-LSCs
to enhance their immunosuppressive phenotype increas-
ing the key immunomodulator markers PDL-1, PDL-2,
IDO, IL-6, and MCP1 in an inflammatory environment.
Furthermore, this trend did not affect the expression of
the costimulatory markers CD80 and CD86 and the
immune regulator molecule PD-1. In particular we ob-
served minimal positivization of the major histocom-
patibility (MHC) class II cell surface receptor unlike
the cytokine stimulated BM-MSCs used as internal
controls of stemness (5.8 ± 1.0% vs. 60.4 ± 4.5%; p
<0.01) (Additional file 1A). These data clearly suggest
that f-LSCs are superior immunomodulators with re-
spect to BM-MSCs and have minimal immunogenicity
even in an inflammatory environment.
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Inhibitory effect of f-LSCs on TCR-triggering activated
PBMCs from healthy donors and after mixed leukocyte
reactions
f-LSCs were cocultured with anti-CD3 stimulated
PBMCs from healthy volunteers at a ratio of 1:50 for
72 h. Using phase-contrast microscopy we observed that
activated lymphocytes formed countless quantities of cell
clumps of different sizes in the absence of f-LSCs. How-
ever, the number of cell clumps was significantly re-
duced after f-LSC coculture and the majority of
lymphocytes were individually distributed in the
medium or closely adhered to the f-LSCs. In the trans-
well system the lymphomonocyte density and blastiza-
tion rate was slightly lower than that of the activated
PBMCs alone (Fig. 2a). Comparable results were ob-
tained in mixed leukocyte reactions with the addition
of f-LSCs (Additional file 2A).
f-LSCs cause cell cycle arrest of activated PBMCs from
healthy donors
MSCs were found to arrest T cells in the G0/G1 phase
of the cell cycle. This form of T-cell unresponsiveness,
which is triggered by MSCs, is not the classical form of
anergy but is referred to as “tolerance arrest” in T cells
[26]. To explore this effect, DNA content was measured
using PI staining in activated PBMCs from healthy do-
nors under different coculture conditions. Analysis of
the cell cycle showed that 22.4 ± 5.3% of PBMCs after
a b
c d
Fig. 1 Immunophenotyping of f-LSCs. a The immunological profile of fibroblast-like limbal stem cells (f-LSCs) was assessed by means of flow
cytometry before (left panel) and after (right panel) 48 h of cytokine-treatment (IL-1β, IL-6, and IFNγ, 500 U/ml) for the human leukocyte antigens
(HLA-DR), the immune T-activator molecule programmed death-1 (PD-1, CD279) and its ligands (programmed death-ligand 1/2 (PDL-1/2)), the
negative regulator of T cell response B7-H4 and the costimulatory molecules CD80 (B7-1) and CD86 (B70/B7-2). All histogram plots include the
percentage of expression of each protein as a representative value of five independent experiments. b qRT-PCR shows the expression of several
immunosuppressive and tolerogenic markers (HLA-G, transforming growth factor beta (TGF-β), indoleamine-pyrrole 2,3-dioxygenase (IDO),
cyclooxygenase-2 (COX-2), hepatocyte growth factor (HGF), PDL-1/2, Fas, Fas-L, monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), and
autoimmune regulator (AIRE)) compared to the bone marrow-derived mesenchymal stem cell (BM-MSC) positive control (upper panel). The same
markers were tested in f-LSCs after cytokine stimulation. The fold change for each gene was calculated with the Delta Delta Ct method using the
Rotor Gene Q software and the expression was normalized for the housekeeping gene β-actin. c f-LSCs were cultured with the abovementioned
Th1 cytokines for 48 h in T-25 flasks. After acutase-mediated dissociation, 106 cells were used for AO/EB staining. Pictures show the viability of
untreated and cytokine treated cells using a fluorescein filter in a 40× objective. d Proliferation assay (MTT) at 48 h for untreated and cytokine-
treated f-LSCs. All data/pictures are representative of at least five independent experiments. Values on the bars are shown as mean ± SE; *p < 0.05,
**p < 0.02, ***p < 0.01
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72 h of activation were in the G2/S phase. In the pres-
ence of f-LSCs, most cells (85.0 ± 1.2%) remained in the
G0/G1 phase, almost like the unstimulated control cells
(94.0 ± 2.8%), while in the transwell system no significant
inhibition of PBMC proliferation was observed (20.2 ±
3%) (Fig. 2b). A previous study on T-cell cycle entry de-
fined a commitment point at early G1 where cells decide
whether to enter the cell cycle; it is associated with the
induction of cyclin D1 expression [27]. To identify the
specific point at which T-cell proliferation was arrested
by f-LSCs we evaluated the expression of the principal
molecules involved in cell cycle regulation. For this pur-
pose, PBMCs from healthy volunteers were stimulated
with anti-CD3 in the presence or absence of f-LSCs and
evaluated by qRT-PCR for expression of cyclin D1 and
p27Kip1 as G1 phase-specific markers. Unstimulated
PBMCs with or without f-LSCs exhibited constitutive
levels of cyclin D1 and a high expression level of the
negative cell cycle regulatory protein p27Kip1. In re-
sponse to anti-CD3, cyclin D1 did not change in expres-
sion whereas p27Kip1 was significantly downregulated
to induce cell cycle entry. Notably, the expression of
p27Kip1 was induced in stimulated PBMCs that had
been cocultured with f-LSCs suggesting the possibility
that f-LSCs exerted their growth inhibitory effect
primarily through induction of p27Kip1 expression
(Additional file 2B). For all coculture experiments hu-
man BM-MSCs served as internal positive controls, re-
vealing a capacity for inhibition of proliferation 10%
higher than that of f-LSCs in healthy activated PBMCs
after coculture (Additional file 3A and B).
T-cell inhibition by f-LSCs is not due to induction of
apoptosis
To test whether or not the inhibitory effect of f-LSCs
was associated with the apoptotic event, AO/EB staining
was concurrently assessed with active caspase-3 detec-
tion by flow cytometry. AO/EB was used to distinguish
between quiescent, activated, and proliferating cells and
to measure apoptosis. After 72 h of culture, PBMCs
stained orange and started to show marks of necrotic
death, as indicated by ethidium bromide intercalation.
After 72 h activated PBMCs appeared uniformly green,
bigger, and with a bulky cytoplasm. In coculture with f-
LSCs the same cells appeared fewer in number, not
apoptotic or necrotic, but still moderately activated
(Fig. 3a). Jurkat cells treated for 4 or 24 h with human
activating anti-Fas (CH11 clone) were used as apoptotic
positive controls (Additional file 4A) showing many
apoptotic body formations and bright green dots in the
nuclei as a consequence of chromatin condensation and
nuclear fragmentation. Late apoptotic cells were ob-
served with condensed and fragmented nuclei, especially
after 24 h of anti-Fas treatment. Confirming these obser-
vations, the percentage of active caspase-3-positive cells
in the presence of f-LSCs and under transwell conditions
showed 6.0 ± 2.8% and 4.3 ± 0.5% of positivity, respect-
ively. Overall, these data suggest that f-LSCs inhibit the
a
b
Fig. 2 Inhibitory effect of f-LSCs on PBMC proliferation. a Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were stimulated
with anti-CD3 for 72 h in the presence or absence of fibroblast-like limbal stem cells (f-LSCs) (1:50 ratio). The f-LSCs drastically reduced the clump
formation after coculture. In the transwell system the lymphomonocyte density was slightly lower than activated PBMCs alone, used as positive
controls. No activated PBMCs served as negative controls. Original magnification: 40×. Pictures are representative of at least five independent
experiments. b DNA content was assessed using PI staining and analyzed by flow cytometry. FACS plots are representative of five experiments of
identical design. Values on the bars are shown as mean ± SE; **p < 0.02, ***p < 0.01
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proliferation of PBMCs mainly by nonapoptotic mecha-
nisms. The weak involvement of apoptosis in immuno-
suppression of lymphocytes induced by BM-MSCs is
shown in Additional file 5A and has been confirmed in
the past by others [28, 29].
Regulation of f-LSCs on conventional activation markers
in the CD3+ subset, CD4+/CD8+ ratio, and CD4+CD25+
regulatory T lymphocytes
To evaluate immune regulation of f-LSCs on T subsets,
f-LSCs were cocultured for 72 h with purified T cells
from healthy volunteers in the presence of anti-CD3/28
mAbs and analyzed by flow cytometry for some conven-
tional activation molecules (CD28, PD-1, CD69) and for
CD4 and CD8 T-surface markers. After coculture we
found marked downregulation of the two activation
markers CD28 and PD-1 in T cells collected from young
volunteers (50.5 ± 3.3% vs. 25.8 ± 3.2% and 17.0 ± 1.0%
vs. 5.1 ± 1.6%, respectively). Higher levels of CD69 (21.0
± 1.9% vs. 39 ± 4.0%) were detected under the same con-
ditions (Fig. 4a) inside the CD3+ T-cell subset. Further-
more, after f-LSC stimulation the percentages of total
CD4+ increased (19.3 ± 0.8% vs. 27.3 ± 0.2%) whereas the
CD8+ fraction level was similar to the control (13.1 ±
0.5% vs. 11.0 ± 0.2%). Ultimately, the CD4/CD8 ratio was
appreciably upregulated (Fig. 4b). This result suggested
that f-LSCs may display regulation on the activation sta-
tus of T-cell compartments and on CD4+ and CD8+ T-
cell subsets. CD28, PD-1, and CD69 expression was
found to be downregulated on activated CD3+ T cells
upon stimulation with BM-MSCs for 72 h, confirming
the different nature of the two stem cell populations and
mechanism of action in immunomodulation induction.
A similar trend in the inversion of the CD4/CD8 ratio
inside the purified pool of T cells after coculture with
BM-MSCs was found (Additional file 5B and C). We
next investigated whether the inhibitory effects of f-
LSCs involved expansion of Treg cells, which are CD4
+CD25highFoxp3+ T cells capable of modulating tolerance
in immune response [30]. We performed flow cytomet-
ric analysis for CD4+CD25+ cells from T cells of healthy
controls after 3 days of incubation with f-LSCs in the
presence of anti-CD3/28 mAbs. We found a faint reduc-
tion in the CD4+CD25+ fraction among stimulated lym-
phocytes as shown in Fig. 4c. This could be the
consequence of a lower activation regimen induced by f-
LSCs on T cells. Notably, inside the gated CD4+CD25high
population no differences in percentage of CD4+Foxp3+
cells were detected when f-LSCs were added to the cul-
ture. As expected, and as previously proved by others,
the CD4+Foxp3+ regulatory T cells were minimally ex-
panded from BM-MSCs after coculture (82 ± 5.9% vs. 94
± 3.2%) (Additional file 5D) [31–33].
Taken together, these results indicated that f-LSCs dis-
played immune regulation on both CD4+ and CD8+ T-
cell subsets.
Comparison of inhibitory effects induced by f-LSCs in
PBMCs from female HT patients and healthy donors
Next, using CFSE, we compared the proliferation rate of
responding PBMCs from healthy controls and female
HT patients stimulated with anti-CD3 mAbs with or
a
b
Fig. 3 The immunosuppressive effects of f-LSCs is not mediated by apoptotic mechanisms. a AO/EB staining was performed as described in the
Methods section on healthy PBMCs. The experiments included the following conditions: fresh unstimulated peripheral blood mononuclear cells
(PBMCs), activated for 72 h with anti-CD3 mAbs, after coculture with fibroblast-like limbal stem cells (f-LSCs), and in the transwell system for the
same time lapse. No typical signs of apoptotic event were observed under all four conditions. Original magnification: 40×. All pictures are representative
of five independent experiments. b Active caspase-3 was detected by FACS showing a very faint involvement of apoptotic cascade in activated healthy
PBMCs after 72 h of coculture with f-LSCs. FACS plots are representative of five experiments of identical design
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without f-LSCs for 72 h. Unstimulated PBMCs without
f-LSCs were used as negative controls. The proliferation
index, useful for determining the antiproliferative effects
of f-LSCs on activated lymphocytes, was calculated as
the sum of cells in all generations divided by the number
of original parent cells. The CFSE results are shown in
Fig. 5a and were similar to those obtained using manual
counting. Specifically, PBMCs from healthy volunteers
and female patients, grown in culture without mitogen
antibodies, after a 7-day period of incubation yielded a
proliferation index of 1.44 ± 0.08 and 1.43 ± 0.1, respect-
ively (negative controls). Antibody stimulation signifi-
cantly increased the proliferation of lymphocytes
(proliferation index 2.5 ± 0.1 in healthy controls vs. 3.84
± 0.5 in female patients). The coculture of stimulated
PBMCs with f-LSCs produced a proliferation index of
1.75 ± 0.1 in volunteers vs. 2.27 ± 0.5 in female patients,
representing a significant impairment of PBMC activa-
tion that was slightly more marked in lymphocytes from
patients compared to healthy controls. The 48 h cyto-
kine prelicensing of f-LSCs with IL6, IL-1β, and IFN-γ
did not significantly improve their immunosuppressive
performance, reducing the lymphocyte-blastization
rate approximately to the same levels as untouched f-
LSCs (Fig. 5a).
f-LSCs downmodulate in vitro production of inflammatory
cytokines
Several studies have suggested that MSCs modulate the
differentiation, function, and balance of the Th1, Th2,
and Th17 subpopulations and foster development of an
anti-inflammatory immune response [34]. To identify
a
b
c
Fig. 4 f-LSCs negatively regulate the proliferation of CD4+, CD8+ lymphocytes and the induction of CD4+CD25+ regulatory T cells. a Representative
dot plots of activated purified T cells collected by healthy volunteers and stained for the three activation markers CD28, programmed death (PD-1),
and CD69 (left panel) are shown. Samples were run after 72 h of incubation with or without fibroblast-like limbal stem cells (f-LSCs). b A representative
flow staining of activated CD4+ and CD8+ lymphocytes alone or after coculture is shown (left panel). In the right section the consequential CD4/CD8
ratio was calculated. c Gating strategy used to detect the CD4+CD25highFoxp3+ fraction in T cells collected by healthy volunteers and stimulated with
anti-CD3/CD28 for 3 days with or without f-LSCs. In all experiments unstimulated PBMCs were used as a negative control. Numbers in the corner of
each quadrant correspond to the percentage of the corresponding cell population inside any dot plot. Also shown are the average results from five
independent experiments. Data are presented as means ± SE in each histogram; *p < 0.05, **p < 0.02. NC normal control
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factors that could be involved in immunosuppressive ef-
fects mediated by f-LSCs, production of proinflamma-
tory or immunosuppressive cytokines and expression of
the transcription factors ROR-γT were investigated by
means of intracellular flow staining. The results showed
that, in activated T cells from female HT patients, intra-
cellular production of IFN-γ, IL-17A, and ROR-γT was
considerably decreased in cocultured cells compared to
untreated controls (18.0 ± 2.1% vs. 9.0 ± 1.9%; 35.2 ± 6.5%
vs. 18.4 ± 3.4%; 27.0 ± 4.5% vs. 14.0 ± 2.6%, respectively).
In contrast, at the same levels f-LSCs did not inhibit ex-
pression of the aforementioned cytokines on T cells from
healthy controls (5.1 ± 1.4% vs. 4.4% ± 1.9%; 8.8 ± 1.2%
vs. 7.0 ± 3.4%; 12.5 ± 6.5% vs. 11.0 ± 5.6%, respectively).
Notably, IL-4 secretion by Th2 was induced in the pres-
ence of f-LSCs, especially in lymphocytes from female
patients (15.0 ± 2.1% vs. 28.5 ± 3.9%) compared to
healthy donors (15.0 ± 2.6% vs. 17.5 ± 1.5%) (Fig. 5b).
These data suggest that the activation of naive T cells to-
ward a Th1 or Th17 immunophenotype depended on an
inflammatory milieu, as in HT-activated T cells, and was
attenuated in the presence of f-LSCs. These results
show, for the first time, the capability of f-LSCs to
downmodulate production of inflammatory cytokines by
activated lymphocytes of female HT patients. This action
could be due to a superior inflammatory background
level present in the T cells collected from patients com-
pared to healthy controls.
Discussion
Hashimoto’s thyroiditis (HT) or chronic lymphocytic
thyroiditis is an autoimmune disease in which the thy-
roid gland is attacked by a variety of cell- and antibody-
mediated immune processes [18]. This condition is the
most common cause of hypothyroidism in the world in
individuals older than 6 years and is about seven times
more frequent in women than in men. To date, no clin-
ical approach has aimed to treat the immunological
cause of a chronic disease like HT; it is only possible to
a
b
Fig. 5 Immunomodulatory effects induced by f-LSCs in PBMCs/T cells harvested from female HT patients. a Peripheral blood mononuclear cell
(PBMC) proliferation was assessed by the CFSE method after 7 days of coculture and analyzed with FACS. The proliferation index (PI) correlated
with the number of cell divisions that PBMCs had undergone. b A comparison of FASC analysis for interferon gamma (IFN-γ), interleukin (IL)-4,
IL-17A, and ROR-γT expression in activated purified T cells collected from female Hashimoto’s thyroiditis (HT) patients and healthy donors after
3 days with or without fibroblast-like limbal stem cell (f-LSC) stimulation. Data are derived from one of the five independent experiments and are
presented, inside the histogram, as means ± SE; *p < 0.05, **p < 0.02
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control its symptoms and clinical manifestations through
lifetime thyroid hormone replacement therapy.
Multiple studies have demonstrated the immunoregu-
latory properties of MSCs. MSCs profoundly affect the
immune response through interactions with the cellular
components of the innate (natural killer (NK) cells) and
adaptive (dendritic cells, B lymphocytes, and T lympho-
cytes) immune systems. MSC immunoregulation can
occur through cellular contact and/or the secretion of
diverse factors [35]. Cells with the characteristics of
MSCs represent a heterogeneous population of stem
cells that have been isolated from almost every type of
tissue stroma sharing their principal immunomodulatory
and regenerative properties. In human limbus we
recently identified stromal fibroblast-like stem cells (f-
LSCs) characterized by robust proliferative capacity,
stable expression of several pluripotent stem cell
markers, self-renewal ability, and multilineage potential.
Here, we show, for the first time, that these cells effi-
ciently inhibit lymphocyte proliferation and modulate
cytokine production. FACS and qRT-PCR analysis re-
vealed the hypoimmunogenity of f-LSCs as they did not
express the complete pattern of molecules required to
fully activate T cells. Specifically, they were negative for
the MHC class II and costimulatory (CD80 or CD86)
molecules, the hematopoietic markers CD34 and CD45,
and the epithelial marker ΔNp63 [13, 14]. Their immune
privileged phenotype is also due to both cell contact and
the soluble factors produced. Among them we detected
the following: TGF-β, PDL-1/2, HLAG, IDO, IL-6, HGF,
COX-2, and MCP-1 (CCL2). Most importantly human f-
LSCs differed from our positive control (BM-MSCs) for
the more elevated expression of HGF, COX-2, and MCP-1.
HGF and TGF-1β were the first molecules described in
MSC-mediated immune regulation of alloantigen-activated
T lymphocytes. Both cytokines can independently diminish
alloantigen-activated T-lymphocyte proliferation, although
proliferation was partially re-established through blocking
antibodies [36]. Prostaglandin E2 (PGE2) is a lipid medi-
ator derived from the conversion of arachidonic acid to
prostaglandin through COX1 and COX2 enzyme action.
PGE2 has been shown to diminish proliferation, stimulate
the secretion of IL-4 and IL-10, and promote CD4+CD25
+Foxp3+ [37].
IFN-γ is a proinflammatory cytokine that can induce
expression of HLA class II (HLA-DR) molecules in
many cell types including BM-MSCs. By contrast, f-
LSCs act as “smart immunomodulators”, improving their
phenotype and their expression for some immune regu-
latory mediators after exposure to several Th1 cytokines
(IL-6, IL-1β, IFN-γ). Consequently their immunosup-
pressive potential is expected to be superior in all those
autoimmunity diseases, including HT, with a Th1-driven
pathogenesis [17]. Furthermore, the natural immune
privileged state and hypoimmunogenicity of f-LSCs can
revoke the need for HLA matching in case of reinfusion
of re-educated lymphomonocytes in patients even if an
inflammatory status exists. As a consequence of their
sensitivity to inflammation we demonstrated that human
f-LSCs adjust their phenotype after 48 h of Th1 cytokine
treatment, maintaining, at baseline, mRNA expression
for HLA-G, TGF-β, IDO, and AIRE; they preserve at
sustained levels the mRNA for COX-2 and HGF, upreg-
ulate the mRNA for MCP-1 and IL-6, and considerably
increase PDL-1 and PDL-2 expression at the protein
level. In addition, no significant impact on HLA-DR and
costimulatory molecules, both critical for immune re-
sponse activation, was observed. Upregulation of PDL-1
and PDL-2 in f-LSCs could be involved in inhibition of
lymphocyte proliferation and also associated with the de-
crease in IFN-γ and IL-17A levels as observed in female
HT-derived T cells. The high expression of COX-2 enzyme,
as a source of PGE2, could favor Th2-like cytokine secre-
tion by inhibiting both Th1- and Th17-associated prolifera-
tion and, at the same time, by enhancing the production of
Th2-associated cytokines such as IL-4. Upregulation of the
chemotactic molecule MCP-1 could help the attraction of
T cells into close proximity of f-LSCs, where high concen-
trations of cytotoxic factors synergistically may act to
suppress T-cell function. Since f-LSC effects on immuno-
competent cells were not MHC restricted and did not need
to be matched with host HLAs, we cocultured human f-
LSCs with allogenic PBMCs from healthy donors and fe-
male HT patients in the presence of anti-CD3 activating
antibodies. We showed that, during coculture, f-LSCs
failed to induce a full allogeneic T-lymphocyte response,
suppressing up to 40% of PBMC proliferation as shown by
cell cycle analysis and CFSE detection. When cell to cell
contacts were blocked by transwell insertion, f-LSCs were
less effective in inducing immunosuppression, suggesting
the hypothesis that both surface and intracellular mole-
cules were necessary to mount a proper immune response.
We also demonstrated that, in the presence of f-LSCs, acti-
vated PBMCs were arrested in the G0/G1 cell cycle phase.
This phenomenon, at the molecular level, was mediated by
upregulation of the cyclin-dependent kinase inhibitor 1B
(p27Kip1). No morphological changes, characteristic of
apoptosis, were observed; nor was the possibility of trigger-
ing caspase-3 activity in PBMCs after coculture.
Having demonstrated that f-LSCs were able to inhibit
allogeneic lymphocyte responses, we further explored the
possible mechanisms underlying these effects. As an im-
portant effector cell, CD8+ T cells play a critical role in im-
mune surveillance of the human body [38]. However,
increasing evidence has demonstrated that CD8+ T cells
also contribute to initiation and progression of several auto-
immune diseases. Our data revealed that the CD4/CD8 ra-
tio had been significantly inverted in healthy activated
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PBMCs after f-LSC interaction, proving a negative regula-
tion action of f-LSCs on the CD8+ T subset. The conven-
tional activation markers CD28 and PD-1 were reasonably
downmodulated in the CD3+ subset while CD69 expression
was significantly induced after coculture. It is important to
note that CD69 was previously regarded as an activation
marker of lymphocytes and a target of the canonical nu-
clear factor kappa-B (NF-kB) signaling [39, 40]. Recently,
studies in CD69-deficient mice have revealed that it might
act as a negative regulator and self-control molecule during
lymphocyte activation and that in an immunoregulatory
context late and sustained CD69 expression is promoted by
noncanonical NF-kB signaling [41]. Therefore, stable CD69
expression defines cells with immunoregulatory properties.
The activation status of PBMCs was also investigated by
assessing expression of CD25. Flow cytometry analyses in-
dicated a faint reduction in CD25 expression and preserva-
tion of the CD4+FoxP3+ pool in the presence or absence of
f-LSCs. These data suggested that the suppressive effect of
f-LSCs was not mediated through induction of regulatory T
cells. Forty-eight hour cytokine prelicensing of f-LSCs with
IL-6, IL-1β, and IFN-γ did not significantly improve their
immunosuppressive performance on female HT PBMCs,
suggesting that the proinflammatory background is not a
necessary condition to induce the immunological effects of
f-LSCs. The identification of helper T (Th) cell subsets has
greatly improved our understanding of regulation of im-
mune effector functions. Th subset differentiation is known
to be regulated by the cytokine environment [42]. In our
in vitro coculture model, f-LSCs seemed to influence the
Th subset balance by altering the cytokine profile of T lym-
phocytes collected from female HT patients. By decreasing
T-lymphocyte expression of IFN-γ, IL-17A, and RORγT,
human f-LSCs might have attenuated the differentiation of
naive CD4+ T cells into Th1 and Th17 effectors. In parallel,
IL-4 expression was improved, shifting the total balance
from Th1-driven responses to a more anti-inflammatory
Th2 profile. ROR-γT is a key transcription factor for Th17
cell differentiation and important for IL-17A expression
in vivo and in vitro. Our results showed downregulation of
ROR-γ at the protein level, suggesting the capability of
f-LSCs to also modulate the Th17 differentiation in favor of
IL-4-producing Th2 cells. This phenomenon was more
evident in T cells cocultured with f-LSCs and isolated from
female patients. This effect may be due to an inflammatory
background able to stimulate or maintain the immune
process in AITD patients [43].
Conclusions
In conclusion, we believe that due to all the features
mentioned human f-LSCs are potent modulators of T
cells. However, mechanisms exclusive to f-LSC-mediated
immunomodulation warrant further investigation. In
addition, as an easily accessible source of stem cells with
a minimal and well-established surgical procedure,
f-LSCs represent an excellent opportunity for use on a
massive scale and as a cellular tool to induce tolerance
in autoreactive lymphocytes from HT patients or other
immunological disorders.
Additional files
Additional file 1: Immunophenotyping of BM-MSCs. (A) The immunological
profile of BM-MSCs was assessed by flow cytometry before (upper panel) and
after 48 h of cytokine-treatment (IL-1β, IL-6, and IFNγ, 500 U/ml) (lower panel)
using the same Abs for f-LSC immune characterization. All histogram plots
include the percentage of expression of each protein as representative value
of five independent experiments. (PDF 572 kb)
Additional file 2: f-LSCs arrest T-cell division. (A) One-way mixed
leukocyte reaction (MLR) was carried out by seeding 2 × 105 of responder
healthy PBMCs into 48-well plates (Corning) and adding 1 × 105
mytomycin-C pre-treated stimulator cells for a final volume of 500 μl of
lymphocyte medium. Each responder and stimulator cell population was
seeded in triplicate. When MLRs were cocultured with f-LSCs the allogenic
activation was greatly reduced. Pictures are representative of five
independent experiments. (B) Molecular detection of p27Kit and
CCND1 mRNA by qRT-PCR. Results are shown as mean ± SD of three
independent experiments; *p < 0.05. (PDF 138 kb)
Additional file 3: Inhibitory effect of BM-MSCs on PBMC proliferation.
(A) PBMCs from healthy volunteers were stimulated with anti-CD3 for
72 h in the presence or absence of BM-MSCs (1:10 ratio). No activated
PBMCs served as negative controls. Original magnification: 40×. Pictures
are representative of at least five independent experiments (B). DNA
content was assessed using PI staining and analyzed by flow cytometry.
Analysis of cell cycle showed the 28 ± 2.7% of PBMCs after 72 h of activation
in G2/S phase. The same cells in the presence of BM-MSCs became 15 ±
3.0% confirming the inhibitory action of BM-MSCs on PBMC proliferation. In
the transwell system no significant inhibition of PBMC growing was
observed (26.2 ± 3%). Unstimulated control cells were used as negative
controls. FACS plots are representative of five experiments of identical
design. Values on the bars are shown as mean ± SE; *p < 0.05. (PDF 488 kb)
Additional file 4: Jurkat cells as a positive control for apoptosis
detection. (A) Untreated Jurkat cells (first row) or treated with activating
anti-Fas for 4 or 24 h (second and third row, respectively) after AO/EB
staining. The arrows indicate many apoptotic body formations, bright
green dots in the nuclei as a consequence of chromatin condensation
and nuclear fragmentation. Late apoptotic cells were observed with
condensed and fragmented nuclei especially after 24 h of anti-Fas
treatment. Original magnification: 40×. All pictures are representative of
five independent experiments. (PDF 240 kb)
Additional file 5: Immunomodulation mechanism played from BM-
MSCs on healthy activated PBMCs. (A) Acitive-caspase-3 detection by
FACS revealed weak induction of the apoptotic cascade in activated
healthy PBMCs after 72 h of coculture with BM-MSCs. FACS histogram
plots are representative of five experiments of identical design. (B) The
expression percentage of the three activation markers (CD28, PD-1, CD69)
in activated healthy PBMCs were assessed by flow cytometry and reported
in the histogram. Samples were run after 72 h of incubation with or without
BM-MSCs. (C) The CD4/CD8 ratio was calculated from data obtained by flow
staining in samples of healthy activated PBMCs alone and after coculture
with BM-MSCs. (D) Detection of CD4+CD25highFoxp3+ fraction in purified T
cells collected from healthy volunteers and stimulated with anti-CD3/CD28
for 3 days with or without BM-MSCs. In all experiments unstimulated PBMCs
were used as negative controls. Data are presented as means ± SE in each
histogram; *p < 0.05, **p < 0.02. (PDF 381 kb)
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